CAR-T Cell Therapy Outcomes: The UCSD Experience
نویسندگان
چکیده
منابع مشابه
New development in CAR-T cell therapy
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell mal...
متن کاملNext frontiers in CAR T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy is entering a new era, transitioning from an experimental approach being tested in a handful of centers to a more mainstream and broadly investigated therapeutic platform with significant efforts directed towards commercial translation. CARs are synthetic receptors engineered and transduced into T cells to redirect T-cell cytotoxicity by recognitio...
متن کاملChimeric Antigen Receptor (CAR) T-Cell Therapy.
Surgery, chemotherapy, and radiation therapy have been the foundation of cancer treatment. Advances in the field of immunology (a branch of science that studies all aspects of the immune system) have led to a greater understanding of the ways in which the body’s own defenses can be used for treatment of blood cancers. Cancer researchers are now studying how the immune system can help destroy ca...
متن کاملGlobal Manufacturing of CAR T Cell Therapy
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types. Chimeric antigen receptor T cells are generated by removing T cells from a patient's blood and engineering the cells to express the chimeric a...
متن کاملCAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens
Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Transplantation and Cellular Therapy
سال: 2021
ISSN: 2666-6367
DOI: 10.1016/s2666-6367(21)00261-x